Literature DB >> 29904202

Total intravenous anesthesia using a midazolam-ketamine-xylazine infusion in horses: 46 cases (2011-2014).

Turi K Aarnes1, Phillip Lerche1, Richard M Bednarski1, John A E Hubbell1.   

Abstract

This study evaluated use of midazolam, ketamine, and xylazine (MKX) for total intravenous (IV) anesthesia (TIVA) in horses. Medical records of 46 horses undergoing a clinical procedure using MKX for TIVA were reviewed. Age, breed, procedure, heart rate (HR), respiratory rate (RR), pre-anesthetic drugs, induction drugs, and total volume of MKX were recorded. Duration of anesthesia, time to standing, number of attempts to stand, and recovery score were also recorded. All horses were premedicated with an alpha-2 adrenoceptor agonist and anesthesia was induced with ketamine and midazolam. Duration of MKX infusion was 33 ± 14 min. Heart rate and RR decreased during the infusion of MKX. Time to endotracheal extubation was 19 ± 12 min. Horses stood at 33 ± 13 min. Median number of attempts to stand was 1. Maintenance of anesthesia of horses with MKX was useful for a variety of procedures and recovery from anesthesia was good.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29904202      PMCID: PMC5901856     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  15 in total

1.  Prolongation of anesthesia with xylazine, ketamine, and guaifenesin in horses: 64 cases (1986-1989).

Authors:  J E McCarty; C M Trim; D Ferguson
Journal:  J Am Vet Med Assoc       Date:  1990-12-15       Impact factor: 1.936

2.  The confidential enquiry into perioperative equine fatalities (CEPEF): mortality results of Phases 1 and 2.

Authors:  G M Johnston; J K Eastment; Jln Wood; P M Taylor
Journal:  Vet Anaesth Analg       Date:  2016-11-15       Impact factor: 1.648

3.  Cardiopulmonary effects of continuous intravenous infusion of guaifenesin, ketamine, and xylazine in ponies.

Authors:  S A Greene; J C Thurmon; W J Tranquilli; G J Benson
Journal:  Am J Vet Res       Date:  1986-11       Impact factor: 1.156

4.  A comparison of romifidine and xylazine when used with diazepam/ketamine for short duration anesthesia in the horse.

Authors:  C L Kerr; W N McDonell; S S Young
Journal:  Can Vet J       Date:  1996-10       Impact factor: 1.008

5.  Evaluation of concentrated solutions of guaifenesin for equine anesthesia.

Authors:  J L Grandy; W N McDonell
Journal:  J Am Vet Med Assoc       Date:  1980-04-01       Impact factor: 1.936

6.  The use of sedatives, analgesic and anaesthetic drugs in the horse: an electronic survey of members of the American Association of Equine Practitioners (AAEP).

Authors:  J A E Hubbell; W J A Saville; R M Bednarski
Journal:  Equine Vet J       Date:  2010-09       Impact factor: 2.888

7.  Comparison of respiratory function during TIVA (romifidine, ketamine, midazolam) and isoflurane anaesthesia in spontaneously breathing ponies Part I: blood gas analysis and cardiorespiratory variables.

Authors:  Barbara Steblaj; Stijn Schauvliege; Kiriaki Pavlidou; Frank Gasthuys; Ioannis Savvas; Luc Duchateau; Lidia Kowalczyk; Lidia Kowalczk; Yves Moens
Journal:  Vet Anaesth Analg       Date:  2014-08-07       Impact factor: 1.648

8.  Pharmacokinetics of midazolam after intravenous administration to horses.

Authors:  J A E Hubbell; E M Kelly; T K Aarnes; R M Bednarski; P Lerche; Z Liu; J Lakritz
Journal:  Equine Vet J       Date:  2013-03-12       Impact factor: 2.888

9.  Clinical evaluation of an infusion of xylazine, guaifenesin and ketamine for maintenance of anaesthesia in horses.

Authors:  L E Young; D H Bartram; M J Diamond; A S Gregg; R S Jones
Journal:  Equine Vet J       Date:  1993-03       Impact factor: 2.888

10.  Comparison of the cardiopulmonary effects of anesthesia maintained by continuous infusion of romifidine, guaifenesin, and ketamine with anesthesia maintained by inhalation of halothane in horses.

Authors:  Rose M McMurphy; Lesley E Young; David J Marlin; Karen Walsh
Journal:  Am J Vet Res       Date:  2002-12       Impact factor: 1.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.